Back to Screener

Healthcare

Pharmagreen Biotech Inc.(PHBI)

Live Price

Offline

$0.0007

-30.00% today

1Y Change

+11.11%

Window

Jun 23, 2025 โ†’ Jun 15, 2026

Market Cap
โ€”
Revenue Growth
+13.7%
EPS Growth
-25.0%
Dividend Yield
0.0%

Coverage: 247 bars ยท Jun 23, 2025 โ†’ Jun 15, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Pharmagreen Biotech Inc. (PHBI) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 11.1% across the available one-year price window (Jun 23, 2025 โ†’ Jun 15, 2026). Baseline metrics include revenue growth of +13.7%, EPS growth of -25.0%, a dividend yield of 0.0%. What stands out right now is revenue +13.7%, EPS -25.0%, free cash flow +62.0% with operating margin -37.5% and ROIC 14.1%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PHBI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+13.7% vs +7.6% peer median

Operating Margin

Below sector median

-37.5% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 11, 2026, but the surprise data is still limited.

The operating picture looks softer than before

Revenue is at +13.7% and EPS is at -25.0%, with operating margin around -37.5%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged -17.9% over the next 5 trading days and finished higher after 1 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
May 11, 2026
โ€”-5.0%-65.0%-57.5%
2026
Feb 10, 2026
โ€”+4.8%-9.5%-19.0%
2025
Dec 8, 2025
โ€”+2.3%+20.9%+62.8%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

PHBI

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

PHBI Max Drawdown

-80.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for PHBI and SPY.

Calendar-year return history is still loading or unavailable.
Pharmagreen Biotech Inc. logo

Company Overview

Pharmagreen Biotech Inc.

Other OTC

Pharmagreen Biotech Inc., a biotech sciences solutions company, focuses on the production of starter plantlets for CBD hemp and medical cannabis industries. The company was incorporated in 2007 and is headquartered in Coquitlam, Canada.

Leadership
Peter Wojcik
IPO Date
Aug 15, 2018
Street Address
2987 Blackbear Court
Mailing
Coquitlam, BC, V3E 3A2
Region
Coquitlam, BC, CA
Reporting Currency
USD
Investor Line
702-803-9404
Last Updated
May 3, 2026
CIK: 0001435181ISIN: US71716C1099CUSIP: 71716C109
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
0.3
Price/Book
โ€”

Growth

Revenue
+13.7%
EPS
-25.0%
Free Cash Flow
+62.0%

Profitability

Gross Margin
-0.0%
Operating Margin
-37.5%
Net Margin
-16.3%
ROE
13.3%
ROIC
14.1%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
0.05

Earnings Reports

๐Ÿ“… Last reportedMay 11, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
May 11, 26
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Feb 10, 26
-0.00
Est โ€”
โ€”
3422.1B
Est โ€”
โ€”
โ€”
Dec 8, 25
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Aug 15, 25
0.00
Est โ€”
โ€”
335M
Est โ€”
โ€”
โ€”
May 13, 25
-0.00
Est โ€”
โ€”
637M
Est โ€”
โ€”
โ€”
Feb 12, 25
0.00
Est โ€”
โ€”
828M
Est โ€”
โ€”
โ€”
Dec 10, 24
-0.00
Est โ€”
โ€”
501M
Est โ€”
โ€”
โ€”
Sep 5, 24
-0.00
Est โ€”
โ€”
615M
Est โ€”
โ€”
โ€”
May 23, 24
-0.00
Est โ€”
โ€”
1.1B
Est โ€”
โ€”
โ€”
Dec 31, 23
-0.00
Est โ€”
โ€”
1.2B
Est โ€”
โ€”
โ€”
Sep 30, 23
-0.00
Est โ€”
โ€”
1.4B
Est โ€”
โ€”
โ€”
Aug 14, 23
-0.00
Est โ€”
โ€”
597M
Est โ€”
โ€”
โ€”
May 19, 23
-0.00
Est โ€”
โ€”
963M
Est โ€”
โ€”
โ€”
Feb 14, 23
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jan 17, 23
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Aug 17, 22
0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.